Biotransformation in Liver Disease — MCQs
What is the primary role of Cytochrome P450 enzymes in the liver?
A patient presents with nephrotic syndrome and hypoalbuminemia. Protein binding of which drug is not affected?
Which of the following is not commonly recognized as a hepatotoxic drug?
Which antidiabetic medication is safe in both liver and renal failure?
Which of the following statements represents the most clinically significant aspect of drug metabolism?
Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
Glutathione is maintained in reduced state by the help of ?
In the liver, what is ethanol primarily converted to?
Methanol toxicity causes blindness due to the formation of:
Alcohol is metabolized by all the following pathways except?
Biotransformation in Liver Disease Indian Medical PG Practice Questions and MCQs
Question 1: What is the primary role of Cytochrome P450 enzymes in the liver?
- A. Lipid transport
- B. Oxidation of drugs (Correct Answer)
- C. Carbohydrate synthesis
- D. Protein degradation
Explanation: ***Oxidation of drugs*** - **Cytochrome P450 enzymes** are a superfamily of monooxygenases that primarily catalyze the **oxidation of various endogenous and exogenous substrates**, including drugs [1, 2]. - This oxidative metabolism is a key step in detoxification and elimination of foreign compounds from the body [1]. *Lipid transport* - **Lipid transport** is primarily facilitated by **lipoproteins** and specific **transport proteins** in the blood and within cells. - While P450 enzymes can metabolize some lipids, their primary role is not in lipid transport [2]. *Carbohydrate synthesis* - **Carbohydrate synthesis**, or **gluconeogenesis**, is mainly carried out by enzymes such as **pyruvate carboxylase** and **fructose-1,6-bisphosphatase**. - Cytochrome P450 enzymes do not play a direct role in the synthesis of carbohydrates. *Protein degradation* - **Protein degradation** is largely mediated by the **ubiquitin-proteasome system** and **lysosomal pathways**. - Cytochrome P450 enzymes are not directly involved in breaking down proteins into smaller peptides or amino acids.
Question 2: A patient presents with nephrotic syndrome and hypoalbuminemia. Protein binding of which drug is not affected?
- A. Valproate
- B. Morphine (Correct Answer)
- C. Diazepam
- D. Tolbutamide
Explanation: ***Morphine*** - Morphine is a **low protein-bound drug** (<35%), meaning a significant portion circulates freely. - Therefore, even with **reduced albumin levels** in nephrotic syndrome, the free fraction available for action is not significantly altered. *Valproate* - Valproate is **highly protein-bound** (90-95%), primarily to albumin. - In conditions like nephrotic syndrome with **hypoalbuminemia**, a decreased binding capacity leads to a higher free drug fraction and increased pharmacological effect. *Diazepam* - Diazepam is also **highly protein-bound** (98%), mainly to albumin. - Like other highly bound drugs, **hypoalbuminemia** in nephrotic syndrome would increase its free fraction, potentially leading to increased side effects. *Tolbutamide* - Tolbutamide is another drug with **high protein binding** (>90%), predominantly to albumin. - Reduced albumin levels in nephrotic syndrome would result in a **higher free concentration** of tolbutamide, increasing its hypoglycemic effect and risk of adverse reactions.
Question 3: Which of the following is not commonly recognized as a hepatotoxic drug?
- A. Chlorpropamide
- B. Allopurinol
- C. Streptomycin (Correct Answer)
- D. Halothane
Explanation: ***Streptomycin*** - Streptomycin is primarily associated with **ototoxicity** (vestibular and cochlear damage) and **nephrotoxicity** (kidney damage), not significant hepatotoxicity. - While most drugs can theoretically cause liver injury, streptomycin is not frequently cited as a major hepatotoxin in clinical practice. *Chlorpropamide* - This **sulfonylurea oral hypoglycemic agent** can cause a range of liver injuries, from asymptomatic enzyme elevations to severe **cholestatic hepatitis** or hepatocellular damage. - Its hepatotoxic potential is well-documented, leading to its decreased use compared to newer antidiabetic agents. *Allopurinol* - Allopurinol, used to treat **gout** and hyperuricemia, is known to cause a variety of adverse effects, including **hypersensitivity reactions** that can involve the liver. - It can lead to **hepatocellular injury**, cholestasis, or mixed liver damage, sometimes as part of a severe drug reaction with eosinophilia and systemic symptoms (**DRESS syndrome**). *Halothane* - Halothane is a potent **halogenated inhalational anesthetic** historically associated with a rare but severe form of idiosyncratic liver injury known as **halothane hepatitis**. - This condition involves **massive hepatic necrosis** and has a high mortality rate, leading to its eventual replacement by newer anesthetics.
Question 4: Which antidiabetic medication is safe in both liver and renal failure?
- A. Linagliptin (Correct Answer)
- B. None of the options
- C. Insulin
- D. Both
Explanation: ***Linagliptin*** - **Linagliptin** is unique among **DPP-4 inhibitors** and antidiabetic medications because it is primarily excreted unmetabolized via the **biliary/fecal route** (80-90%), with only minimal renal excretion - This unique pharmacokinetic profile makes it the **only antidiabetic medication that requires NO dose adjustment** in **renal impairment** of any severity, including end-stage renal disease - It is also **safe in hepatic impairment** as only a small fraction undergoes hepatic metabolism - **No dose adjustment needed** in either renal or hepatic failure makes it truly "safe" in both conditions *Insulin* - While insulin can be **used** in patients with renal and hepatic failure, it is **NOT considered safe without dose modification** - **In renal failure:** Insulin clearance decreases significantly, leading to **prolonged half-life** and increased risk of **hypoglycemia** → requires **dose reduction** (often 25-50% decrease) - **In hepatic failure:** Impaired gluconeogenesis and altered insulin metabolism increase hypoglycemia risk → requires **careful dose reduction and monitoring** - The need for significant dose adjustments and increased monitoring means insulin does NOT meet the criteria of being "safe" in both conditions without modification *Both* - This option is **incorrect** because while both medications can be used in renal and hepatic failure, only **linagliptin** is truly safe without dose adjustment - **Insulin requires substantial dose reduction** in both conditions due to decreased clearance and altered metabolism - In pharmacology, "safe" implies use without major modifications; insulin's requirement for careful dose titration disqualifies it from this definition *None of the options* - This is incorrect because **linagliptin** clearly meets the criteria of being safe in both liver and renal failure without dose adjustment - Linagliptin's predominantly non-renal excretion pathway is a well-established pharmacological advantage
Question 5: Which of the following statements represents the most clinically significant aspect of drug metabolism?
- A. Most common enzyme involved is CYP 3A4/5 (Correct Answer)
- B. Glucuronidation is a phase II reaction
- C. Reduction is a phase I reaction
- D. Cytochrome P450 is involved in phase I reactions
Explanation: ***Most common enzyme involved is Cyp 3A4/5*** - CYP3A4/5 is the **most abundant and clinically significant** cytochrome P450 enzyme, responsible for metabolizing approximately **50% of all clinically used drugs**. - Its widespread involvement means variations in its activity (due to **genetics, drug interactions, or disease**) have a major impact on drug efficacy and toxicity. *Glucuronidation is a phase II reaction* - While correct that glucuronidation is a **Phase II metabolic reaction**, this statement describes a biochemical classification rather than a clinically significant aspect compared to the involvement of CYP3A4/5. - Phase II reactions generally involve **conjugation** to increase water solubility and facilitate excretion, but they do not collectively account for as many drug interactions as CYP3A4/5 alone. *Reduction is a phase I reaction* - This statement is factually correct as **reduction** is indeed a **Phase I metabolic reaction**. - However, it represents a generic classification of a metabolic pathway and doesn't highlight the specific clinical importance or prevalence of a particular enzyme or reaction in drug metabolism. *Cytochrome P450 is involved in phase I reactions* - This is true; the **cytochrome P450 system** is the primary enzyme system for **Phase I metabolism**, which introduces or exposes polar groups to make drugs more reactive. - While fundamentally important, this statement is too broad; it does not specify the most clinically significant *aspect* or *enzyme* within the P450 system compared to directly identifying CYP3A4/5.
Question 6: Which of the following combinations can result in severe toxicity due to inhibition of cytochrome P450 enzymes?
- A. Amiodarone + Atorvastatin
- B. Carbamazepine + Atorvastatin
- C. Atorvastatin + Itraconazole (Correct Answer)
- D. Phenytoin + Atorvastatin
Explanation: ***Atorvastatin + Itraconazole*** - **Itraconazole** is a potent inhibitor of **CYP3A4**, the primary enzyme responsible for atorvastatin's metabolism. - Co-administration leads to significantly increased **atorvastatin plasma concentrations**, raising the risk of severe side effects like **rhabdomyolysis** and **hepatotoxicity**. *Amiodarone + Atorvastatin* - **Amiodarone** is a moderate **CYP3A4 inhibitor** and can increase atorvastatin levels, but the inhibition is **less potent** than itraconazole. - While this combination does carry a risk and requires dose adjustment, the interaction is **less severe** compared to the potent inhibition seen with itraconazole. - The direct CYP inhibition leading to severe atorvastatin toxicity is less pronounced than with itraconazole. *Carbamazepine + Atorvastatin* - **Carbamazepine** is a potent **CYP3A4 inducer**, meaning it would increase the metabolism of atorvastatin, potentially *decreasing* its efficacy rather than causing toxicity through inhibition. - This interaction would typically lead to subtherapeutic atorvastatin levels, rather than severe toxicity. *Phenytoin + Atorvastatin* - **Phenytoin** is also a potent **CYP3A4 inducer**, similar to carbamazepine. - Concurrent use would likely lead to enhanced metabolism and **reduced efficacy of atorvastatin**, not increased toxicity due to enzyme inhibition.
Question 7: Glutathione is maintained in reduced state by the help of ?
- A. Transamination
- B. HMP shunt (Correct Answer)
- C. Uronic acid pathway
- D. Glycogenesis
Explanation: ***HMP shunt*** - The **hexose monophosphate (HMP) shunt** produces **NADPH**, which is crucial for reducing **oxidized glutathione** back to its reduced form via **glutathione reductase**. - **Reduced glutathione** protects cells from **oxidative damage** by detoxifying harmful **reactive oxygen species.** *Transamination* - **Transamination** is a process involving the transfer of an **amino group** from an amino acid to a keto acid. - This pathway is primarily involved in **amino acid metabolism** and the synthesis of **non-essential amino acids**, not directly in glutathione reduction. *Uronic acid pathway* - The **uronic acid pathway** is involved in the synthesis of **glycolipids**, **sugars**, and **vitamin C** (in some animals). - It does not directly produce **NADPH** or enzymes necessary for maintaining **glutathione** in its reduced state. *Glycogenesis* - **Glycogenesis** is the process of synthesizing **glycogen** from **glucose** for storage, typically occurring in the liver and muscles. - This pathway is involved in **glucose storage** and **energy regulation**, not in the **redox state of glutathione**.
Question 8: In the liver, what is ethanol primarily converted to?
- A. Methanol
- B. Pyruvate
- C. Acetaldehyde (Correct Answer)
- D. Oxaloacetate
Explanation: **Explanation:** The metabolism of ethanol primarily occurs in the liver through a series of oxidative reactions. The first and rate-limiting step involves the conversion of **ethanol to acetaldehyde**. This reaction is catalyzed by the cytosolic enzyme **Alcohol Dehydrogenase (ADH)**, which utilizes $NAD^+$ as a co-factor, reducing it to $NADH$. Acetaldehyde is a highly reactive and toxic intermediate responsible for many of the adverse effects of alcohol consumption (e.g., nausea, tachycardia). It is subsequently converted to acetate by Mitochondrial Aldehyde Dehydrogenase (ALDH2). **Analysis of Incorrect Options:** * **Methanol (A):** Methanol is a different type of alcohol (wood alcohol). It is not a metabolite of ethanol; rather, it is metabolized by the same enzyme system into toxic formaldehyde and formic acid. * **Pyruvate (B):** Pyruvate is the end-product of glycolysis. While ethanol metabolism increases the $NADH/NAD^+$ ratio, this actually shifts the equilibrium *away* from pyruvate, converting it into lactate instead (leading to lactic acidosis). * **Oxaloacetate (D):** Oxaloacetate is an intermediate of the TCA cycle and gluconeogenesis. High levels of $NADH$ from ethanol metabolism cause oxaloacetate to be diverted to malate, contributing to the inhibition of gluconeogenesis and subsequent fasting hypoglycemia. **High-Yield Clinical Pearls for NEET-PG:** 1. **Disulfiram (Antabuse):** Inhibits **Aldehyde Dehydrogenase**, causing acetaldehyde accumulation. This leads to the "Disulfiram-like reaction" (flushing, vomiting), used as a deterrent in chronic alcoholism. 2. **Fomepizole:** Inhibits **Alcohol Dehydrogenase**; it is the preferred antidote for methanol or ethylene glycol poisoning. 3. **Metabolic Derangements:** Ethanol metabolism increases the $NADH/NAD^+$ ratio, leading to hypoglycemia, lactic acidosis, and fatty liver (steatosis) due to increased fatty acid synthesis.
Question 9: Methanol toxicity causes blindness due to the formation of:
- A. Formic acid (Correct Answer)
- B. Formaldehyde
- C. Lactic acid
- D. Pyruvic acid
Explanation: **Explanation:** Methanol toxicity is a classic high-yield topic in biochemistry and toxicology. The toxicity of methanol is not due to the parent compound itself, but rather its metabolic byproducts. **1. Why Formic Acid is correct:** Methanol is metabolized in the liver via two sequential oxidation steps: * **Step 1:** Methanol is converted to **Formaldehyde** by the enzyme *Alcohol Dehydrogenase*. * **Step 2:** Formaldehyde is rapidly converted to **Formic Acid (Formate)** by *Aldehyde Dehydrogenase*. While formaldehyde is transient and highly reactive, **Formic acid** is the primary metabolite responsible for clinical toxicity. It inhibits mitochondrial **Cytochrome c oxidase** (Complex IV), leading to cellular hypoxia. The retina and optic nerve are particularly sensitive to this metabolic inhibition, resulting in optic papillitis, retinal edema, and permanent **blindness**. **2. Analysis of Incorrect Options:** * **B. Formaldehyde:** Although it is the first metabolite formed, it has a very short half-life and is quickly converted to formic acid. Formic acid is the substance that actually accumulates and causes the specific ocular damage. * **C. Lactic Acid:** Methanol toxicity causes a high anion gap metabolic acidosis. While lactic acid may rise secondary to tissue hypoxia, it is not the direct cause of the specific visual toxicity. * **D. Pyruvic Acid:** This is a normal intermediate of glycolysis and is not a toxic byproduct of methanol metabolism. **Clinical Pearls for NEET-PG:** * **Antidote:** **Fomepizole** (inhibits Alcohol Dehydrogenase). Ethanol can be used as a competitive inhibitor if Fomepizole is unavailable. * **Key Lab Finding:** High Anion Gap Metabolic Acidosis (HAGMA) with an increased **Osmolar Gap**. * **Classic Presentation:** "Snowfield vision" (blurred vision) and "Putaminal necrosis" on brain imaging.
Question 10: Alcohol is metabolized by all the following pathways except?
- A. Alcohol dehydrogenase
- B. MEOS (Microsomal Ethanol Oxidizing System)
- C. Catalase
- D. Aldehyde dehydrogenase (Correct Answer)
Explanation: **Explanation:** The question asks for the pathway that does **not** metabolize alcohol (ethanol) itself. **Why Option D is the Correct Answer:** Alcohol metabolism occurs in two distinct stages. In the first stage, **Ethanol** is converted into **Acetaldehyde**. In the second stage, Acetaldehyde is converted into Acetate. **Aldehyde dehydrogenase (ALDH)** is the enzyme responsible for the *second* stage (oxidizing acetaldehyde). Therefore, while ALDH is part of the overall ethanol metabolism *chain*, it does not metabolize alcohol itself; it metabolizes its byproduct. **Why the other options are incorrect:** The following three systems are the primary pathways that directly oxidize **Ethanol to Acetaldehyde**: * **Alcohol Dehydrogenase (ADH):** The major pathway (cytosolic) responsible for the bulk of alcohol metabolism under normal conditions. It requires $NAD^+$ as a coenzyme. * **MEOS (Microsomal Ethanol Oxidizing System):** Located in the smooth endoplasmic reticulum, this pathway uses **Cytochrome P450 (specifically CYP2E1)**. It becomes significantly active at high blood alcohol levels (chronic alcoholism). * **Catalase:** A minor pathway located in **peroxisomes**. It plays a negligible role in the liver but may be involved in brain ethanol metabolism. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting step:** The conversion of ethanol to acetaldehyde by ADH is the rate-limiting step (follows **Zero-order kinetics**). * **Disulfiram (Antabuse):** Inhibits **Aldehyde Dehydrogenase**, leading to the accumulation of acetaldehyde, which causes nausea, flushing, and tachycardia. * **Methanol Poisoning:** Fomepizole is used as an antidote because it inhibits Alcohol Dehydrogenase, preventing the formation of toxic formaldehyde.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free